I don't post calls publicly often... This is a message for the fund mangers and traders on here that employ a strategy of squeezing naked shorts by accumulating a position once its deemed another funds cost average has become to low from an exhausted short campaign. This method has done exceptionally well for me the last two years. Take a look at INGN. They are a company doing affiliated research with MD. Anderson here in Houston. There is a hedge fund naked shorting it and has been, make a few calls to UBS for color and you will find out who. This fund is being way over zealous. Sources tell me their cost average is now to low. INGN is a loaded spring with an FDA decision or buyout right around the corner. Examine the pipeline and see this company is not a one drug entity. The current drug Advexin has a safer profile than even already approved Erbitux. A food critic turned self proclaimed biotech expert, by the name of Adam F. who is a writer for the street has been meticulously bashing the stock with what he thinks is journalism. The goal is to get the stock delisted because the fund that is short is in to deep and would not be able to cover even if it wanted to, as an act of desperation they are going for broke. It would take over 30 days to cover, if the shares even existed to cover. This is one of those trades that can blow away your high watermark, and make your portfolio year. Do your own due diligence, but I thought I would put it out there and document my call for when the FDA decision is made. INGN and MD Anderson will put Texas on the map as a biotech power house, and vanguard in gene therapy.